Author Index to Volume 11

Al-Ahdal, M.N., 145
Aldridge, K.E., 29
Ampel, N.M., 65
Amsterdam, D., 209
Arens, M., 137
Astorga, A., 177

Barry, A.L., 29, 159
Bartholomew, W.R., 209
Bellido Barbero, J., 53
Bello, H., 109
Berlin, O.G.W., 125
Bradbury, W., 101
Brewer, T.C., 25
Brooks, R., 205
Brown, L., 205
Bruckner, D.A., 25, 87, 125

Chatterjee, N.K., 129
Chia, W.K., 101
Chmel, H., 215
Crist Jr., A.E., 21

Deibel, R., 129
Dennehy, P.H., 201
Dhar, R., 195
Dilworth, V., 137
Drake, T.A., 125
Drulak, M., 181
Dugger, K.O., 65
Dunkley L, 101

Eikman, E.A., 215
Ernst, J., 163
Ertle, A.R., 87

Forward, K.R., 61
Franke, J.J., 41
Franklin, R., 205
Fuchs, P.C., 29

Galgiani, J.N., 65
Garcia, A., 109
Garcia, L., 25
García-Rodriguez, J.A., 53
García-Sanchez, J.E., 53
Gauntlett, D.R., 201
Gerarden, T., 1
Gong Jr., H., 87
González, C., 109

Hadfield, T., 177
Herron Jr., R.M., 125
Hindler, J.A., 125
Hira, P.R., 195
Hocko, M., 209
Hsiung, D., 181

Inderlied, C.B., 87

Johnson, S.M., 81
Jones, R.N., 29, 159

Kaehler, M., 129
Kallay, M.C., 171
Khan, G.Y., 145
Klotz, S.A., 117
Krisher, K.K., 171

Lastimoza, J.L., 195
Law, J.H., 65
LeBar, W.D., 21
Liu, S., 151
Lorian, V., 163

Manion, F.A., 41
McGarry, T.J., 145
Meng, L., 121
Meyer, R.D., 151
Muñoz Bellido, J.L., 53

Naik, S.P., 11
Nolte, F.S., 171

Ortiz de la Tabla, V., 53

Palmer, J.A., 215
Parisi, J.T., 121
Pfaller, M.A., 1
Piper, J., 177

Qadri, S.G.M., 145
Qadri, S.M.H., 145

Raybould, T.J.G., 181
Reary, B.W., 117
Resek, C.M., 21
Ruck, R.E., 11

Samsonoff, W., 11
Sautter, R.L., 21
Scalarone, G.M., 81
Smith, H., 181
Soffer, M.J., 87
del Solar, E., 109
Spence, L., 101
Stratton, C.W., 41
Sun, S.H., 65
Swierkosz, E., 137

Tiosejo, L.L., 209

Urrea, R., 109

Weeks, L.S., 41
Weinstein, M.P., 189
Wenzel, R.P., 1
Winston, S., 181

Yong, J., 181
Yu, M., 1

Zemelman, R., 109

© 1988 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0732-8893/88/$3.50

Subject Index to Volume 11

Achromobacter spp.
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Acinetobacter anitratus,
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem, against, 29
Acinetobacter calcoaceticus
lomefloxacin against, compared to other antimicrobials, 189
MDL 19,592 against, 159
Acinetobacter lwoffi
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
pneumonia, nasotracheal protected specimen brush results, 87
Acinetobacter sp.
lomefloxacin against, compared to other antimicrobials, 189
Acquired immune deficiency syndrome (AIDS)
DNA probe activity of *Mycobacterium avium* isolates and, 125
Mycobacterium avium complex organisms in, effect of surface-active agents on, 11
Aeromonas hydrophilia
cefotaxime against, 29
cefpirome against, 29
HRE against, 29
Agar
chocolate, 117
lisogenic phage replication onto, 121
salt containing, 177
Agar plates
sheep blood, 177
Agglutination
slide, for brucellosis diagnosis, 195
Agglutination assay
latex, detection of *Herpes simplex* antibody, 21
Agglutination tests
latex, cerebrospinal fluid, for bacterial meningitis, 61
Agglutinins
cold, 101
AIDS, *See* Acquired immune deficiency syndrome
Alcoholic patient
malnourished, *Neisseria meningitidis* and *Moraxella osloensis* in blood and peritoneal fluid in, 209
Amikacin
activity, ampicillin and, 163
against, *Pseudomonas aeruginosa*, 151
Aminoglycosides
combined with ciprofloxacin and beta lactams, against multidrug-resistant *Pseudomonas aeruginosa*, 151
synergism with penicillin, against enterococci, 163
Amphoterecin B
antifungal activity of, compared to LY121019, 1
Ampicillin
activity, amikacin and, 163
antibacterial activity of, on gram-negative bacteria, 109
Ansamycin
minimum inhibitory concentrations against *Mycobacterium avium* complex organisms, in AIDS patients, effects of surface-active agents on, 11
Antibodies
Blastomyces dermatitidis, 81
herpes simplex, detection, 21
Histoplasma capsulatum, 81
fluorescent, herpes simplex antibody detection by, 21
IgG, 101
Brucella specific, 195
IgM, 101
Brucella specific, 195
monoclonal
Cryptosporidium, 25
immunofluorescence, 145
total antihuman globulin specific, 195
tube precipitin-type, antigens with specificity for, 65
urease conjugated, 181
Antibody test
indirect fluorescent, for brucellosis diagnosis, 195
Antifungal agents, in vitro activation of, 1
Antigens
detection methods, in bacterial meningitis, 61
hypersensitivity, from *Coccidiodes immitis* spherules, extraction of, 65
K-Le, 81
lysate, yeast phase, *Blastomyces dermatitidis*, preparation of ELISA evaluation of, 81
for rotavirus infection detection, 205
streptococcal, Group A, detection, 181
T 043324, 81
Antihuman globulin specific antibodies, 195
Antimicrobic susceptibility testing, 177
Apnea, 87
Aqueous toluene extraction procedure
obtaining antigens from *Coccidiodes immitis* by, 65
Arthritis
septic, caused by *Mycobacterium terrae* complex organisms, 171
Assays, *See also* Immunoassays
enzyme-linked immunosorbent, 81, 101, 205
Autolytic activities, cell wall,
amikacin and, 163
ampicillin and, 163
Azlocillin
ciprofloxacin antibacterial activity in combination with, 41
against *Pseudomonas aeruginosa*, 151
Aztreonam
in vitro activity, compared to HRE 664, 29

Bacilli, gram positive
aztreonam against, 29
cefotaxime against, 29

© 1988 Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0732-8893/88/$3.50

cefpirome against, 29
HRE 664 against, 29
imipenem against, 29
Bacillus cereus
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
BACTEC 460 blood culture system
for *Francisella tularensis* growth, 117
Bacteremia
Francisella tularensis, 117
microorganisms causing, lomefloxacin and other antimicrobials against, comparative in vitro activity, 189
Bacterial
killing, ampicillin/sulbactam, 109
meningitis, diagnosis, bacterial antigen detection in spinal fluid evaluation for, 61
pneumonia, diagnostic efficacy of nasotracheal protected specimen brush in, 87
Bactericidal testing
ciprofloxacin, beta-lactams and aminoglycosides, against *Pseudomonas aeruginosa*, 151
Bacteriophages
isolation from lysogens, 121
Bacteroides sp.
pneumonia, nasotracheal protected specimen brush results, 87
Beta-lactam agents
antipsuedomonal, ciprofloxacin bactericidal activity in comparison with, 41
combined with ciprofloxacin and aminoglycosides, against *Pseudomonas aeruginosa*, 151
in vitro activity, comparison with HRE 664, 29
Beta lactamase
gram-negative bacteria producing, ampicillin/sulbactam activity against, 109
Biotinylated DNA probes
herpes simplex virus detection by, 145
Blastomyces dermatitidis
yeast phase lysate antigens, preparation of ELISA evaluation of, 81
Blastomycosis
diagnosis, 81
Blood
Francisella tularensis isolation from, 117
Neisseria meningitidis isolated from, in malnourished alcoholic, 209
Blood culture
BACTEC 460, 117
Bordetella sp.
pneumonia, nasotracheal protected specimen brush results, 87
Brahnamella catarrhalis,
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
MDL 19,592 against, 159
pneumonia, nasotracheal protected specimen brush results, 87
Branhamella catarrhalis [RAV]
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazid against, 29
HRE 664 against, 29
imipenem against, 29
Bronchoscopy
flexible fiberoptic, drawbacks, 87
Bronchospasm, 87
Broth
growth in, for methicillin resistant *Staphylococcus aureus* detection, 177
Broth microdilution
for methicillin resistant *Staphylococcus aureus* detection, 177
susceptibility tests, with HRE 664, 29
Brucella melitensis, 53, 195
Brucella spp.
detection, 53
Brucella suis, 53
Brucellosis
pulmonary, 53
Brush
specimen, nasotracheal protected, diagnostic efficacy in bacterial pneumonia, 87

Candida albicans
LY121019 activity against, 1
Candida parapsiilosis
LY121019 activity against, 1
Candida spp
LY121019 activity against, influence of in vitro susceptibility conditions on, 1
Candida tropicalis
LY121019 activity against, 1
Catalase
positive, *Staphylococcus aureus* detection on, 177
Catheter
nasotracheal protected specimen brush, 87
Cefoperazone
cifprofloxacin antibacterial activity in combination with, 41
Cefopergone, 109
Cefotaxime
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
in vitro activity, compared to HRE 664, 29
Cefpirome
in vitro activity, compared to HRE 664, 29
Ceftazidime
cifprofloxacin antibacterial activity in combination with, 41
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
against *Pseudomonas aeruginosa*, 151
in vitro activity, compared to HRE 664, 29
Cell wall
autolytic activities
amikacin and, 163
ampicillin and, 163
Centrifugation
of clinical specimens, effect of recovery of herpes simplex virus, 137
Cephalexin
antimicrobial activity, MDL 19,592 compared to, 159
Cephalosporins
oral, MDL 19,592, 159
Cephapirin
minimum inhibitory concentrations against *Mycobacterium avium* complex organisms, effects of surface-active agents on, 11
Cephems
for staphylococcal treatment, 159
Cephradine
antimicrobial activity, MDL 19,592 compared to, 159
Cerebrospinal fluid
latex agglutination tests, for bacterial meningitis, 61
Children, *See* Infants and children
Chlamydia trachomatis
specimens, sonication of, 137
Chocolate agar culture

Francisella tularensis
growth on, 117
Ciprofloxacin
bactericidal activity, alone, and in combination with β-lactam agents, 41
combined with beta-lactams and aminoglycosides, against multidrug-resistant *Pseudomonas aeruginosa*, 151
minimum inhibitory concentrations against *Mycobacterium avium* complex organisms in AIDS patients, effect of surface-active agents on, 11
Citrobacter
lomeflaxicin against, compared to other antimicrobials, 189
Citrobacter amalonaticus,
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Citrobacter diversus
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Citrobacter freundii
ampicillin against, 109
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazimide against, 29
HRE 664 against, 29
imipenem against, 29
sulbactam against, 109
Clones
Coxsackie virus B4 RNA, 129
Coagulase
positive tube, *Staphylococcus auerus* detection on, 177
Coagulase-staphylococcus
pneumonia, nasotracheal protected specimen brush results, 87
Cocci
gram-positive, MDL 19,592 against, 159
Coccidiioidomycosis, 65
Coccidioides imitis
spherules, hypersensitivity antigens extraction from, 65
Cold agglutinins
for *Mycoplasma pneumoniae* detection, 101
Complement fixation test (CFT)
for detection of antibody against *Mycoplasma pneumoniae*, 101
Computerized axial tomography of soft tissue hematoma, 215
Congenital infection
Herpes simplex antibody detection in, 21
Corynebacterium jeikeium,
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
MDL 19,592 against, 159
Corynebacterium sp.
pneumonia, nasotracheal protected specimen brush results, 87
Coxsackie virus
B4, subgenomic probes, enterovirus detection by, 129
Cryptosporidium
incidence, in patients submitting stool sample, 25
Cysteine
effect on vitro activity of HRE 664, 29
Cystine, 117

Debilitated patient
herpes simplex virus in, 145
Diarrhea
pediatric, rotavirus in, 205
Dimethyl sulfoxide (DMSO)
effect on *Mycobacterium avium* complex organisms in AIDS patients, 11
Diplococci
in blood and peritoneal fluid, 209
Diplococcobacilli
in blood and peritoneal fluid, 209
Disk diffusion test
for methicillin resistant *Staphylococcus aureus* detection, 177
Disseminated meningococcal infection, 209
DNA
hybridization, herpes simplex virus examination by, 145
probe, biotinylated, herpes simplex virus detection by, 145
probe reactivity, of *Mycobacterium avium* complex isolates, AIDS and, 125
Dot hybridization
coxsackie virus B4 detection by, 129
for rotavirus infection detection, 205

Echo 3 probe
coxsackie virus detection by, 129
Echo 9 probe
coxsackie virus detection by, 129
Electron microscopy
for rotavirus detection, protein-stabilized Rotazyme II test compared to, 205
Empyema
pulmonary, brucellar, 53
Encephalitis
herpes simplex antibody detection in, 21
Endotracheal brushing
in bacterial pneumonia, 87
Enoxacin
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
Enterobacter aerogenes
aztreonam against, 29
cefotaxime against, 29
cefpirome, against, 29
ceftazimide against, 29
HRE 664 against, 29
imipenem against, 29
lomeflaxicin against, compared to other antimicrobials, 189
Enterobacter agglomerans,
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazimide against, 29
HRE 664 against, 29
imipenem against, 29
Enterobacter cloacae
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazimide against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
Enterobactereiceae
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
MDL 19,592 against, 159
Enterococci
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29

ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
MDL 19,952 against, 159
penicillin and aminoglycoside synergism against, 163
Enterococcus
Group D, pneumonia, nasotracheal protected specimen brush results, 87
Enterococcus faecalis
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Enterococcus faecium
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Enterococcus spp.
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Enterovirus
detection, using subgenomic probes of coxsackie B4 virus by hybridization, 129
Enzyme
inhibition, sulbactam and, 109
Enzyme immunoassay
Group A streptococcal antigen detection by, 181
Pathfinder Rotavirus, 201
Testpack Rotavirus, 201
Enzyme-linked immunosorbent assay (ELISA)
Blastomyces dermatitidis yeast phase lysate antigen evaluation by, 81
herpes simplex antibody detection by, 21
rotavirus infection detection by, 205
urease conjugated, for IgM and IgG antibodies against *Mycoplasma pneumoniae* in human sera, 101
Escherichia coli
amikacin against, 163
ampicillin against, 109, 163
aztreonam against, 29
cefotaxime against, 29
cefpirome, against, 29
ceftazimide against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
MDL 19,592 against, 159
pneumonia, nasotracheal protected specimen brush results, 87
Escherichia hermanii
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Ethylenediaminetetraacetic acid (disodium salt, EDTA)
effect on *Mycobacterium avium* complex organisms in AIDS patients, 11
Eubacterium sp.
pneumonia, nasotracheal protected specimen brush results, 87

Fanconi's pancytopenia
Mycobacterium terrae complex in, 171
Fecal specimens
rotavirus detection in enzyme immunoassay for, 201
protein-stabilized Rotazyme test, comparison with standard Rotazyme II and electron microscopy, 205
Fever
soft tissue hematoma as cause of, 215
Fiberoptic bronchoscopy
flexible, drawbacks, 87
Fluorescent antibody technique
brucellosis diagnosis by, 195
herpes simplex antibody detection by, 21
5-Fluorocytosine
antifungal activity, compared to LY12109, 1
Francisella tularensis
isolation, from blood, 117

Gastrointestinal symptoms
in children, rotavirus, in 205
Gel filtration
hypersensitivity antigen separation by, 65
Gentamicin
against *Pseudomonas aeruginosa*, 151
GMB, nonenteric
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Gram stain
nasotracheal protected specimen brush, 87
Staphylococcus aureus detection on, 177
Gram-negative bacteria
ampicillin and sulbactam activity against, 109

Haemophilus influenzae
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
pneumonia, nasotracheal protected specimen brush results, 87
Hemagglutination
indirect, 21
Herpes simplex antibody
detection of, rapid latex agglutination assay and fluorescent-antibody technique comparisons in, 21
Herpes simplex virus
detection, by biotinylated DNA probes, 145
recovery of clinical specimens, effect of sonication and centrifugation on, 137
Histoplasma capsulatum
antibodies, 81
Histoplasmosis
specimens, *Blastomyces dermatitidis* yeast phase lysate antigen sensitivity and cross-reactivity with, 81
HRE 664
in vitro evaluation, 29
Hybridization
DNA, herpes simplex virus examination by, 145
dot, 129, 205
enterovirus detection using subgenomic probes of coxsackie virus B4 by, 129
Hypersensitivity
delayed-type, coccidioidal, 65
Hypersensitivity antigens
from *Coccidiodes immitis* spherules, extraction of, 65

IgG antibodies

Brucella specific, 195
against *Mycoplasma pneumonia*, detection, 101
IgM antibodies
Brucella specific, 195
against *Mycoplasma pneumonia*, detection, 101
Imipenem
cifprofloxacin antibacterial activity in combination with, 41
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
against *Pseudomonas aeruginosa*, 151
in vitro activity, compared to HRE 664, 29
Immunoassay, *See also* Assays
enzyme, 181
latex agglutination, 181
microwell enzyme, 181
Visuwell enzyme, 181
Pathfinder Rotavirus, 201
TESTPACK Rotavirus, 201
Immunocompromised patient
Cryptosporidium incidence in, 25
herpes simplex antibody detection in, 21
herpes simplex virus in, 145
Immunofluorescence
monoclonal antibody
Cryptosporidium detection by, 25
herpes simplex virus detection by, 145
Immunofluorescent method (IFA),
herpes simplex antibody detection by, 21
Mycoplasma pneumoniae detection, by 101
Immunoperoxidase
histopathology, herpes simplex virus examination by, 145
Immunosorbent assays
enzyme, 21, 81, 101, 205
Incubation temperature
influence on in vitro susceptibility *Candida* species to LY121019, 1
Indirect fluorescent antibody test for brucellosis diagnosis, 195
Indirect hemagglutination (IHA)
herpes simplex antibody detection by, 21
Infants and children
diarrhea, rotavirus in, 205
herpes simplex virus in, 145
septic arthritis in, 171
Inhibitory testing
ciprofloxacin, beta-lactams and aminoglycosides against *Pseudomonas aeruginosa*, 151
Inoculum size
influence on in vitro susceptibility of *Candida* species to LY12109, 1
Inoculum temperature
influence on in vitro susceptibility of *Candida* species to LY121019, 1

Ketoconazole
antifungal activity of, compared to LY121019, 1
Klebsiella oxytoca
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
lomefloxacin against, compared to other antimicrobials, 189
pneumonia, nasotracheal protected specimen brush results, 87
Klebsiella pneumoniae
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
nasotracheal protected specimen brush results, 87
pneumonia, nasotracheal protected specimen brush results, 87

Lactobacillus sp.
pneumonia, nasotracheal protected specimen brush results, 87
Latex agglutination assay
Group A streptococcal antigen detection by, 181
herpes simplex antibody detection by, 21
Latex agglutination tests
cerebrospinal fluid, for bacterial meningitis, 61
for rotavirus infection detection, 205
Listeria monocytogenes
lomefloxacin against, compared to other antimicrobials, 189
Lomefloxacin
comparative in vitro activity, against microorganisms causing bacteremia, 189
Lung biopsy
open, in bacterial pneumonia, 87
Lung disease
nonbacterial, 87
LY121019
anticandidal activity, in vitro susceptibility testing conditions influence on, 1
Lymphocyte transforming activities
antibodies with, 65
Lysate antigens
yeast phase, *Blastomyces dermatitidis*, preparation of ELISA evaluation of, 81
Lysis
bacterial, 121
Lysogens
bacteriophage isolation from, 121

Malnourished patient
Neisseria meningitidis and *Moraxella osloensis* in blood and peritoneal fluid in, 209
MDL 19,592
antimicrobial activity, 159
Medium
composition, influence on in vitro susceptibility of *Candida* species to LY121019, 1
Meningitis
bacterial, diagnosis, bacterial antigen detection in spinal fluid evaluation for, 61
Meningococcal infection
disseminated, 209
Meningococci
MDL 19,592 against, 159
Metabolic inhibition
for *Mycoplasma pneumonia* detection, 101
Methicillin
resistance, among *Staphylococcus aureus* rapid laboratory detection of, 177
Mexlocillin
against *Pseudomonas aeruginosa*, 151
Microagglutination test
for brucellosis diagnosis, 195
Microwell enzyme immunoassay
detection of Group A streptococcus in throat swab specimens, 181
Minimum inhibitory concentrations (MIC)

ampicillin, sulbactam and, 109
β-lactams, 41
ciprofloxacin, 41
Mitoymcin C
broth medium containing, 121
Monoclonal antibody, immunofluorescence
Cryptosporidium detection by, 25
herpes simplex virus detection by, 145
Moraxella atlantoe
distinguished from M. *osloensis*, 209
Moraxella bovis
distinguished from M. *osloensis*, 209
Moraxella lacunata
distinguished from M. *osloensis*, 209
Moraxella nonliquefaciens
distinguished from M. *osloensis*, 209
Moraxella osloensis
from peritoneal fluid, in malnourished alcoholic, 209
Moraxella phenylpyruvica
distinguished from M. *osloensis*, 209
Moraxella urethralis
distinguished from M. *osloensis*, 209
Morganella morganii
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
MRS test
for methicillin resistance among *Staphylococcus aureus*, 177
Mycobacterium avium complex organisms, in AIDS patient
DNA probe reactivity, 125
drug susceptibility levels and effect of surface-active agents on, 11
Mycobacterium intracellulare
DNA probe reactivity of, AIDS and, 125
Mycobacterium nonchromogenicum
primary pulmonary infection caused by, 171
Mycobacterium terrae complex organisms
primary pulmonary infection caused by, 171
Mycobacterium triviale
primary pulmonary infection caused by, 171
Mycoplasma pneumoniae
in human sera, IgM and IgG antibodies against, detection of, urease conjugated enzyme-linked immunosorbent assays for, 101

Nasotracheal protected specimen brush
diagnostic efficacy, in bacterial pneumonia, 87
Neisseria gonorrhoeae
HRE 664 inhibition of, 29
Neisseria meningitidis
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
isolation from blood, in malnourished alcoholic, 209
MDL 19,592 against, 159
Neisseria spp
MDL 19,592 against, 159
Norfloxacin
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
Nosocomial infection
bacteriophage typing in, 121
Nucleic acid, *See also* DNA; RNA
hybridization, detection of entoviruses using subgenomic probes of coxsackie virus B4 by, 129
probes, coxsackie virus B4 detection by, 129

Ofloxacin
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
Oropharynx
cross-reaction with organisms in, 181
Osteomyelitis
Mycobacterium terrae complex in, 171
Oxacillin
growth on, for methicillin resistant *Staphylococcus aureus* detection, 177
staphylococci resistant and susceptible to, HRE 664 inhibition of, 29

Pancytopenia
Fanconi's, 171
Pathfinder Rotavirus immunoassay, 201
Pediatrics, *See* Infants and children
Penicillin
synergism with aminoglycosides, against enterococci, 163
Percutaneous lung aspiration drawbacks, 87
Periplasmic space
sulbactin penetration in, 109
Peritoneal fluid
Moraxella osloensis from in malnourished alcoholic, 209
pH
influence on in vitro susceptibility of *Candida* species to LY121019, 1
Phages, *See* Bacteriophages
Pharmacokinetics
MDL 19,592, 159
Piperacillin
cifprofloxacin antibacterial activity in combination with, 41
against *Pseudomonas aeruginosa*, 151
Plasmid
-cured strains, E. *coli*, 109
Pneumonia
bacterial, diagnostic efficacy of nasotracheal protected specimen brush in, 87
Protein-stabilized Rotazyme II test
comparison with standard Rotazyme II and electron microscopy, 205
Proteus mirabilis
aztreonam against, 29
cefotaxime against, 29
cefpirome, against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
Proteus vulgaris
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidine against, 29
HRE 664 against, 29
imipenem against, 29
Providencia rettgeri
aztreonam against, 29
cefotaxine against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Providentia stuartii
aztreonam against, 29
cefotaxime against, 29

cefpirome, against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Pseudomonas aeruginosa
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
clinical isolates, bactericidal activity of ciprofloxacin alone and in combination with β-lactam agents, 41
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
multidrug-resistant, ciprofloxacin, beta-lactams and aminoglycosides against, 151
Pseudomonas cepacea
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Pseudomonas fluorescens
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Pseudomonas maltophilia
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
lomefloxacin against, compared to other antimicrobials, 189
Pseudomonas spp.
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
MDL 19,592 against, 159
Pulmonary infection
brucellosis, 53
primary, caused by *Mycobacterium terrae* complex, 171
tuberculosis like, 125

Quinolone antimicrobials
lomefloxacin, 189

Rayon swabs
throat specimens obtained with, 181
Respiratory disease
brucellosis, 53
Respiratory pathogens
nasotracheal protected specimen brush cultures of, 87
Respiratory tract infection
Mycoplasma pneumoniae in, 101
Rheumatoid factor
IgG, 101
Rifampicin
minimum inhibitory concentrations against *Mycobacterium avium* complex organisms, in AIDS patients, effect of surface-active agents on, 11
RMI 19,592, *See* MDL 19,592
RNA
coxsackie virus B4, clones, 129
for rotavirus infection detection, 205
recombinant, DNA probes homologous to, 125
Rotavirus, detection in fecal specimens
enzyme immunoassay for, 201
protein-stabilized Rotazyme II test, comparison with standard Rotazyme II and electron microscopy, 205
Rotazyme II test
protein-stabilized, comparison with standard Rotazyme II and electron microscopy, 205

Salmonella enteritidis,
cefotaxime against, 29
cefpirome against, 29
HRE against, 29
Salt containing agar
for methicillin resistant *Staphylococcus aureus* detection, 177
Saprophytic species
Mycobacterium terrae complex, 171
Serologic testing
herpes simplex antibody detection by, 21
tularemia, 117
Serratia liquefaciens
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Serratia maracesens
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
pneumonia, nasotracheal protected specimen brush results, 87
Serum
human, IgM and IgG antibodies against *Mycoplasma pneumonia*, in detection of, 101
specimens, *Blastomyces dermatitidis* antibodies in, 81
Shigella sonnei
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Skin tests
coccidioidal, 65
Slide agglutination test
for brucellosis, 195
Sodium dodecyl sulfate (SDS)
effect on *Mycobacterium avium* complex organisms in AIDS patients, 11
Soft tissue
hematoma, as cause of fever, 215
Sonication
of clinical specimens, effect on recovery of herpes simplex virus, 137
Spinal fluid
bacterial antigen detection in, bacterial meningitis diagnosis, 61
Sputum
expectorated, drawbacks, 87
Staphylococci
MDL 19,592 against, 159
oxacillin susceptible and resistant, 159
HRE 664 inhibition of, 29
penicillin and aminoglycoside synergism against, 163
pneumonia, nasotracheal protected specimen brush results, 87
Staphylococci, Coag-Neg.
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Staphylococcus aureus
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobial agents, 189
MDL 19,592 against, 159
methicillin resistant, rapid laboratory detection, 171

oxacillin resistant and susceptible
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Staphylococcus capitis, 159
Staphylococcus epidermidis, 159
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
lomefloxacin against, compared to other antimicrobials, 189
oxacillin-resistant
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
rapid isolation, 121
Staphylococcus haemolyticus,
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Staphylococcus hominis, 159
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Staphylococcus pneumoniae
lomefloxacin against, compared to other antimicrobials, 189
Staphylococcus saprophyticus, 159
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Staphylococcus simulans, 159
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Staphylococcus warneri, 159
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Stool specimen
Cryptosporidium incidence from, 25
Streptococci
HRE 664 inhibition of, 29
Streptococcus
Group A, in throat swab specimens, detection, Visuwell enzyme immunoassay for, 181
Group D (non-enterococcus), pneumonia, nasotracheal protected specimen brush results, 87
Groups C and G
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
pneumonia, nasotracheal protected specimen brush results, 87
viridans group, pneumonia, nasotracheal protected brush specimen results, 87
Streptococcus agalactiae 29
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Streptococcus agalactiae (B),
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Streptococcus bovis
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Streptococcus faecalis
amikacin and ampicillin activity against, 163
Streptococcus pneumoniae, 159
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
penicillin-resistant and susceptible
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
pneumonia, nasotracheal protected specimen brush results, 87
Streptococcus pyogenes
cefotaxime against, 29
cefpirome against, 29
HRE 664 against, 29
Streptococcus pyogenes (A),
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
Streptococcus spp
beta-hemolytic, MDL 19,592 against, 159
Stuarts medium, 181
Sulbactam
antibacterial activity of, on gram-negative bacteria, 109
Surface-active agents
effects on drug susceptibility levels and ultrastructure of *Mycobacterium avium* complex organisms in AIDS patients, 11
Susceptibility testing
antimicrobic, 177
broth microdilution, with HRE 664, 29
in vitro, influence on LY121019 anticandidal activity, 1
Synergy
in vitro studies, with ciprofloxacin and beta-lactam agents and aminoglycosides against multidrug-resistant *Pseudomonas aeuruginosa*, 151
Synovitis
Mycobacterium terrae complex in, 171

Tenosynovitis
Mycobacterium terrae complex in, 171
TESTPACK Rotavirus immunoassay, 201
Throat swab specimens
Group A streptococcus in, detection, Visuwell enzyme immunoassay for, 181
Tobramycin
against microorganisms causing bacteremia, comparison with lomefloxacin, 189
against *Pseudomonas aeruginosa*, 151
Toluene extraction procedures
aqueous, obtaining antigens from *Coccidoides immitis* by, 65
Transplantation
herpes simplex antibody detection in, 21
Transtracheal aspiration
drawbacks, 87
Tratrazolium
broth containing, 121
2.3.5-Triphenyltetrazolim chloride (TTC), 121
Trypticase soy broth, 121
Tube precipitin-type antibodies
antigens with specificity for, 65
Tuberculosis
miliary, *Mycobacterium terrae* complex infection in, 171
Tuberculosis-like pulmonary infection, 125
Tularemia, 117
Tween 80

effect on *Mycobacterium avium* complex organisms in AIDS patients, 11

Undulent fever
pattern of, 53
Urease conjugated antibodies, 181
Urease conjugated enzyme-linked immunosorbent assays
for IgM and IgG antibodies against *Mycoplasma pneumoniae* detection, 101

Veillonella sp
pneumonia, nasotracheal protected specimen brush results, 87
Viral particles
for rotavirus infection detection, 205
Viridans group staphylococci
pneumonia, nasotracheal protected specimen brush results, 87
Virus infection
respiratory, 101
Visuwell enzyme immunoassay
detection of Group A streptococcus in throat swab specimens, 181

Yeast extract broth, 121
Yeast phase lysate antigens
Blastomyces dermatitidis, preparation of ELISA evaluation of, 81
Yersinia enterocolitica
aztreonam against, 29
cefotaxime against, 29
cefpirome against, 29
ceftazidime against, 29
HRE 664 against, 29
imipenem against, 29
YETS broth, 121